Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Sell rating and announces Price Target of $18.
Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Sell rating and announces Price Target of $18.